Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007. (2018)

First Author: Synnott NC
Attributed to:  Structural biology of the tumour suppressor p53 and its complexes funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.canlet.2017.09.053

PubMed Identifier: 29069577

Publication URI: http://europepmc.org/abstract/MED/29069577

Type: Journal Article/Review

Volume: 414

Parent Publication: Cancer letters

ISSN: 0304-3835